Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in Neoadjuvant Treatment of Rectal Cancer
NCT01152710Phase 2Completed
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Jun 2004
- Primary completion
- Mar 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer, sponsored by Institute of Oncology Ljubljana. Primary endpoint: Complete Pathological Remission Rate at 9 weeks. Started Jun 2004; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01152710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01152710.